About 15% of colorectal cancers are called MSI because they demonstrate microsatellite instability. In most sporadic MSI cases, the DNA mismatch repair (MMR) defect is due to methylation of the MLH1 promoter. In hereditary MSI cases, it is the consequence of germline mutations of one of the MMR genes. We analysed the MLH1 promoter for methylation using the methylationspecific PCR technique. With a previously described and widely used primer set, a number of samples with an intact MMR system were found to have methylated MLH1 promoter, a finding normally associated with lack of MLH1 expression. Another primer set, specific for a more proximal region of the promoter, gave results that correlated more closely with loss of MLH1 expression. We then conducted a survey of the literature on the subject, and a total of 161 articles were examined. Although it was shown as early as 1999 that absence of MLH1 expression correlated with methylation of the proximal but not distal regions of the MLH1 promoter, 60% of published studies analysed nonspecific regions. Our findings suggest that these studies are likely to have wrongly estimated the association between methylation of the MLH1 gene and the lack of its protein expression.
About 15% of colorectal cancers are called MSI because they demonstrate microsatellite instability. In most sporadic MSI cases, the DNA mismatch repair (MMR) defect is due to methylation of the MLH1 promoter. In hereditary MSI cases, it is the consequence of germline mutations of one of the MMR genes. We analysed the MLH1 promoter for methylation using the methylationspecific PCR technique. With a previously described and widely used primer set, a number of samples with an intact MMR system were found to have methylated MLH1 promoter, a finding normally associated with lack of MLH1 expression. Another primer set, specific for a more proximal region of the promoter, gave results that correlated more closely with loss of MLH1 expression. We then conducted a survey of the literature on the subject, and a total of 161 articles were examined. Although it was shown as early as 1999 that absence of MLH1 expression correlated with methylation of the proximal but not distal regions of the MLH1 promoter, 60% of published studies analysed nonspecific regions. Our findings suggest that these studies are likely to have wrongly estimated the association between methylation of the MLH1 gene and the lack of its protein expression. Oncogene (2007)26, 7596-7600; doi:10.1038/sj.onc.1210581; published online 4 June 2007 Keywords: microsatellite instability; HNPCC; MLH1; promoter; methylation In mammalian cells, DNA methylation occurs mainly at cytosine bases in CpG dinucleotides (Bird, 2002) . Most methylated cytosines are found in CpG dinucleotides outside CpG islands which are CpG clusters (Bird, 2002) . The genomes of cancer cells are globally hypomethylated relative to their normal counterparts (Feinberg and Vogelstein, 1983) . CpG islands, particularly those associated with gene promoters (60% of genes have CpG islands) are generally unmethylated, whether the gene is expressed or not (Bird, 1986) . DNA methylation at CpG islands is considered a potent mechanism for silencing gene expression (Kass et al., 1997) , and there is an increasing number of genes reported to show promoter methylation in human cancers (Esteller et al., 2001) .
One of the genes most studied for promoter methylation in cancer is MLH1. This gene forms part of the mismatch repair (MMR) system and it has been shown that its promoter methylation is directly involved in tumor initiation and progression, because cells are consequently unable to repair DNA replication errors due to the resulting MMR defect (Kane et al., 1997) . Generally, DNA replication errors occur at the level of microsatellite repeat sequences and tumors with an MMR defect are termed MSI because they demonstrate microsatellite instability (Boland et al., 1998) . This phenotype is found in about 15% of colorectal, gastric and endometrial tumors (Boland et al., 1998) . MSI tumors may be sporadic or hereditary in patients belonging to hereditary nonpolyposis colorectal cancer (HNPCC) families (Aaltonen et al., 1993; Ionov et al., 1993; Thibodeau et al., 1993) and the main difference is the cause of their MMR defect. In most cases, MSI in sporadic tumors is due to somatic methylation of the MLH1 promoter, whereas MSI in HNPCC is due to germline mutation of one of the MMR genes, mostly MSH2 or MLH1, and less frequently MSH6 or PMS2 (Peltoma¨ki and Vasen, 2004) .
We analysed by methylation-specific PCR (MSP) a series of colorectal cancer cell lines whose MSI status and MMR defects were determined previously (Gayet et al., 2001) . We first used primers specific for methylated or nonmethylated DNA sequences of the MLH1 gene as described by Herman et al. (1998) (Figure 1a) . Twenty-one cell lines were microsatellite stable (MSS) and five of these (24%) showed methylation of the MLH1 promoter (Table 1) . Methylation was also detected in 8 of 14 (57%) MSI cell lines (Table 1) . MMR defects in the MMR genes had already been investigated in 11 of these MSI cell lines (Gayet et al., 2001) . The LS174T and TC71 cell lines contain mutations in the MLH1 and MSH2 genes, respectively, and yet showed methylation of the MLH1 promoter. Together with the five MSS cell lines, a total of seven cell lines therefore showed MLH1 promoter methylation even though they either express this gene or contain a mutation in it. Because of these discordant results between promoter methylation and MLH1 expression, we used other primer pairs specific for a more proximal region of the MLH1 promoter as described by Park et al. (2003) (Figure 1b ). This analysis gave results more compatible with what was expected ( Table 1) . None of the 21 MSS cell lines showed methylation. MLH1 promoter methylation was detected in 6 of the 14 MSI cell lines, but in none of the cell lines containing an MSH2, MLH1 or MSH6 mutation, including the LS174T and TC71 cell lines.
We next used the two different sets of primers to evaluate MLH1 promoter methylation in a series of 34 MSS and 38 MSI primary colorectal tumors (Figures 1c  and d ), whose MSI status was determined using a pentaplex of five quasimonomorphic mononucleotide repeats (Suraweera et al., 2002) . With primers described by Herman et al. (1998) , MLH1 promoter was methylated in 4/34 (12%) MSS tumors, whereas none was found to be methylated using primers described by Park et al. (2003) (Table 1 ). In the 38 MSI tumors, 23 (61%) and 18 (47%) showed MLH1 promoter methylation with the Herman et al. (1998) or Park et al. (2003) primers, respectively. MLH1 and MSH2 expression were examined by immunohistochemistry in these 38 MSI tumors as described previously (Jourdan et al., 2003) . Among the 13 samples not expressing MSH2, four (31%) were positive for MLH1 promoter methylation using the Herman primers but none were positive with the Park primers. In the 25 samples lacking MLH1 expression, methylation was detected in 19 (76%) and 18 (72%) cases with the Herman and Park primers, respectively. All 18 MSI cases showing MLH1 promoter methylation with the Park primers lacked MLH1 expression, whereas four of the 23 MSI cases showing MLH1 promoter methylation with the Herman primers expressed MLH1 normally. It should be noted that contrary to cell lines where there is generally no amplification with the 'unmethylated' primers when the MLH1 promoter is methylated, both 'unmethylated' and 'methylated' primers amplify DNA extracted from primary tumors when MLH1 promoter is methylated. This is due to the presence of contaminating normal or stromal cells within the tumor sample. By mixing various amounts of DNA extracted from a cell line with MLH1 promoter methylation and a cell line without MLH1 promoter methylation, we showed that methylation could be detected when the methylated DNA content was as low as 10% (results not shown). Moreover, the tumor content of the 38 MSI samples used in this study was estimated by analysing the amplification profiles of the BAT-26 and BAT-25 mononucleotide repeats used to determine their MSI status as described previously (Brennetot et al., 2005) . The mean tumor content was 52% and no sample had tumor content below 20%, hence none of the samples in our analysis could have given false-negative results for MLH1 promoter methylation.
We have shown that MSP analysis for MLH1 methylation using the Park et al. (2003) conditions were always negative in MSS and MSI samples in which a functional MLH1 gene was expressed. On the other hand, conditions described by Herman et al. (1998) revealed MLH1 promoter methylation in a number of cases that had normal MLH1 expression. Our MSP results with these two sets of primers showed that only methylation in the proximal region relative to the transcription start site of the MLH1 gene was correlated with an absence of MLH1 expression. These results confirm and extend those of Deng et al. (1999) , who reported that MLH1 silencing correlates with methylation of a specific region of the MLH1 promoter. In their analysis, Deng et al. (1999) defined four regions as A, B, C and D. They showed that absence of MLH1 expression correlated perfectly only with methylation within the C region. Methylation of the D region, although less specific, was also a good indicator of MLH1 silencing. Methylation of the A and B regions was not specific for loss of MLH1 expression. All Herman et al. (1996) . MSP was performed with: panels a and c: primers as reported by Herman et al. (1998) 0 -agagtggatagtgatttttaatgt-3 0 ; unmethylated-antisense, 5 0 -actc tataaattactaaatctcttca-3 0 ). PCR conditions for the Herman primers were 951C for 15 min, followed by 35 cycles of 951C for 30 s, 591C for 45 s and 721C for 30 s. The final extension was at 721C for 4 min. The same conditions were used for the Park primers except that 40 cycles were used, and the annealing temperature was 531C. DNA was extracted from cell lines (panels a and b), or from primary tumors (panels c and d). Results with the two primer sets were concordant for methylated samples (lanes 1 and 4) and unmethylated samples (lanes 3 and 6). They were discordant (methylated with Herman's primers, and unmethylated with Park's primers) in lanes 2 and 5. (Table 2) . A first round of selection, according to the titles, allowed us to exclude reviews and articles that were clearly not relevant, keeping thus a total of 280 articles. We then analysed all articles published in journals with an ISI impact factor for 2004 that was above 3, and available through the INSERM bibliographic service. This selection left 161 articles meeting our inclusion criteria. The experimental procedures for all of these articles were then examined to determine which region(s) of the MLH1 promoter were analysed for methylation.
We considered as specific (for correlation with MLH1 expression), those articles analysing the C (28 papers) or D (11 papers) regions, together with those analysing several regions that included the C region (25 papers). Articles that analysed only A (63 papers), only B (31 papers) or both A and B regions (three papers) were considered as nonspecific. A total of 97/161 (60.2%) of the published literature thus analysed nonspecific regions of the MLH1 promoter. When the analysis was carried out year by year, 100% of the six papers published in 1997-1998 used nonspecific methods. The Deng et al. (1999) paper was published in 1999 when 85.7% of the 14 analysed articles used nonspecific methods. Even after the Deng et al. (1999) publication and although their results were confirmed on several occasions (Miyakura et al., 2001; Samowitz et al., 2005) , the percentage of articles between 2000 and 2006 that analysed nonspecific regions varied from 40 to 84.6% (average 56%).
Four methods were mostly used to evaluate MLH1 promoter methylation: MSP in 82 articles, methylationsensitive restriction analysis in 31, combined bisulfite restriction analysis (COBRA) in 22 and quantitative real-time PCR (MethyLight) in 18. With the exception of methylation-sensitive restriction analysis, all methods require sodium bisulfite pretreatment of DNA, converting unmethylated cytosine nucleotides into uracil, as originally described by Frommer et al. (1992) .
The first report on MLH1 promoter methylation published in 1997 described methylation-sensitive restriction analysis using the HpaII/MspI restriction enzymes (Kane et al., 1997) . Both enzymes recognize the CCGG sequence but HpaII is methylation-sensitive and does not cut DNA when the CpG is methylated. Untreated DNA is digested by one or the other restriction enzyme and then amplified with PCR using primers that flank the restriction site so that only methylated samples will amplify after HpaII digestion. All 31 publications where this method was employed used the same HpaII/MspI enzymes, although primer positions may have differed. Because the four CCGG sites found in the MLH1 promoter are all localized within the B region, all 31 papers analysed MLH1 promoter methylation in a nonspecific region. The MethyLight method was described for the first time in 1999 (Eads et al., 1999) . This method is based on PCR with primers that amplify methylated DNA after bisulfite treatment, together with a fluorescent probe that is also specific for the methylated sequence, thus allowing quantitative measurement of the proportion of methylated DNA as compared to controls. Of the 18 publications using the MethyLight method, 14 used primers and probe for A region sequences, thus making 78% of the papers using MethyLight nonspecific. The first MethyLight study using primers and probe in the specific C region was published in 2004 (Fiegl et al., 2004) .
COBRA was first described in 1997 as a sensitive and quantitative methylation assay, with the human estrogen receptor (ER) gene as a model system (Xiong and Laird, 1997) . Primers used in the PCR do not contain CpG dinucleotides so that both methylated and nonmethylated DNA are equally amplified. The amplified product is then digested with a restriction enzyme specific for a site containing a C nucleotide retained after bisulfite treatment only when CpG is methylated. A number of The most commonly used enzymes were BstUI (CG/CG: four sites in the A region and one site in the C region), Sau3AI (/GATC: one site in the C region), and RsaI (GT/AC: one site in the D region). We found that only two reports using COBRA (9%) were nonspecific. MSP was first described for methylation analysis of the p16, p15, VHL and E-cadherin promoters (Herman et al., 1996) . It is based on the use of primers complementary to bisulfite-modified DNA and specific for sequences with methylated or nonmethylated CpG. The first report using MSP for the MLH1 promoter was published in 1998 (Herman et al., 1998) . It described the 'Herman' primers used in this article and localized to the A region. These same conditions were used in 47 other publications. MLH1 promoter methylation was analysed by MSP in 11 other publications using different primer sets also localized to the A region, thus making a total of 59 publications that used nonspecific MSP conditions. In 29 publications, MSP was performed using primers for the specific C or D regions either alone (23 cases) or in comparison with the A region (six cases). The first sets of MSP primers in the C region were described by Grady et al. (2001) and Yamamoto et al. (2001) with the sense primers beginning 21 and 4 bp upstream of the C region, respectively. They can be considered as specific for the detection of MLH1 promoter methylation associated with MLH1 silencing, as can the primers described later by Park et al. (2003) used in this article.
It is surprising that during the 7 years after the publication of the work of Deng et al. (1999) , 56% of papers continue to analyse regions of the MLH1 promoter in which methylation is not associated with MLH1 silencing. It is mainly in publications using such nonspecific methods that 'MLH1 methylation' was reported in normal tissues or in cancers that are not frequently of the MSI type. It is likely that methylation on the A and B regions are not artifacts, but associated with a more general epigenetic mechanism. However, this is not directly related to the absence of MLH1 expression and further studies are needed to determine its biological significance, if any. Many publications have reported methylation in the promoters of an increasing number of genes in human tumors. 'Classical' genes such as p16, MGMT, E-cadherin and APC give 1156, 503, 333 and 248 hits, respectively, in a PubMed query with 'methylation'. It is likely that different methods were used and different regions of the promoters analysed, although this may not always correlate with silencing of the corresponding gene. A similar survey to the one reported here for MLH1 should thus be undertaken with the aim of clarifying this issue.
The analysis of MLH1 promoter methylation, as related to MLH1 lack of expression, cannot be performed by methylation-sensitive restriction analysis. The other methods can be used provided that correct conditions are chosen, as those reported for MethyLight (Fiegl et al., 2004) , COBRA (Suzuki et al., 1999) and MSP (Yamamoto et al., 2001; Park et al., 2003) . More researchers are now turning to quantitative real-time MSP techniques (MethyLight), but 50% of the 10 articles published in 2006 and using this method analysed a nonspecific region of the MLH1 promoter. Whatever the technique employed, the use of primers and protocols for the C or D regions will avoid the detection of nonspecific methylation as reported in 60% of the published papers in this area. The exact frequencies of somatic MLH1 mutations in sporadic cases, and of MLH1 promoter methylation in HNPCC cases either as a heritable germline epimutation, or as a second inactivating event, are unknown and need to be determined in large tumor series. If it is confirmed that these events are rare, the analysis of MLH1 promoter methylation with appropriate methods should help to discriminate between sporadic and hereditary MSI cases.
Note
During the reviewing process of this manuscript, there were 71 additional publications with MLH1 and methylation as queries in PubMed. Twenty five were examined because they met our inclusion criteria and were easily available to us. Nonspecific conditions were used in 10 articles (40% MSP: 5 cases, Methylight: 2 cases and methylation-sensitive restriction analysis: 3 cases).
